DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS & INFECTIONS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要 确定父母研究ACTG 362中受试者中艾滋病定义的并发症和严重细菌感染的总体比率和风险因素。 次要的 1.确定研究队列中发生心血管疾病的总体比率和危险因素(如甘油三酯、胆固醇、腰臀比)。值得关注的心血管事件包括：心肌梗死、冠状动脉血运重建手术、心绞痛、心脏性猝死和中风。 2.比较艾滋病定义并发症的发生时间和 受试者严重感染或心血管疾病 给那些被分配接受安慰剂的人接受阿奇霉素。 3.评估CD4计数和HIV RNA水平之间的关系 基线和随访期间以及机会性感染和其他 与艾滋病毒相关的并发症。 4.比较被分配接受阿奇霉素治疗的受试者和接受安慰剂治疗的受试者的死亡率。 5.确定符合以下条件的患者的认知恶化风险 严重的免疫抑制，并在服用的同时恢复了CD4计数 高效抗逆转录病毒疗法(HAART)。 6.确定免疫学(CD4计数)和病毒学(血浆HIV RNA 水平)标志物和特定药物(尤其是PI)与 认知能力下降。 7.评估长期坚持使用抗逆转录病毒药物的相关因素 药物和依从性对随时间和时间的病毒抑制的影响 关于机会性和严重细菌感染的发展和 心血管疾病

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Determine the overall rates of and risk factors for AIDS-defining complications and serious bacterial infections in subjects in the parent study, ACTG 362. Secondary 1. Determine the overall rates and risk factors (e.g. triglycerides,cholesterol, waist-to-hip ratio) for the development of cardiovascular disease in the study cohort. Cardiovascular events of interest include: myocardial infarction, coronary artery revascularization procedures, angina, sudden cardiac death, and stroke. 2. Compare the time to development of AIDS-defining complications and serious infections or cardiovascular disease in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 3. Evaluate the association between CD4 counts and HIV RNA levels at baseline and during follow-up and risk of opportunistic infections and other HIV-related complications. 4. Compare mortality in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 5. Define the risk of cognitive deterioration in a cohort of patients who have been severely immunosuppressed and recovered CD4 counts while taking Highly Active Antiretroviral Therapy (HAART). 6. Identify immunologic (CD4 counts) and virologic (plasma HIV RNA levels) markers and specific drugs (especially PIs) associated with cognitive decline. 7. Evaluate factors associated with long-term adherence to antiretroviral medications and the effect of adherence on viral suppression over time and on the development of opportunistic and serious bacterial infections and cardiovascular diseas